EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues

Bae-Hoon Kim iD, Yeon-Ho Chung iD, Tae-Gyun Woo, So-Mi Kang iD, Soyoung Park, Minju Kim, Bum-Joon Park

International Journal of Molecular Sciences · 14.06.2024 · 25 (12) · 6558

DOI: 10.3390/ijms25126558 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.06.2024. Verfasst von Bae-Hoon Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rare Disease R&D Center, PRG S&T Co., Ltd., Busan 46274, Republic of Korea. Hauptthemen laut MEDLINE: Neurofibromatoses, Neurofibromin 2, Neurilemmoma, Skin Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pusan National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NF2-related schwannomatosis (NF2) is a genetic syndrome characterized by the growth of benign tumors in the nervous system, particularly bilateral vestibular schwannomas, meningiomas, and ependymomas. This review consolidates the current knowledge on NF2 syndrome, emphasizing the molecular pathology associated with the mutations in the gene of the same name, the NF2 gene, and the subsequent dysfunction of its product, the Merlin protein. Merlin, a tumor suppressor, integrates multiple signaling pathways that regulate cell contact, proliferation, and motility, thereby influencing tumor growth. The loss of Merlin disrupts these pathways, leading to tumorigenesis. We discuss the roles of another two proteins potentially associated with NF2 deficiency as well as Merlin: Yes-associated protein 1 (YAP), which may promote tumor growth, and Raf kinase inhibitory protein (RKIP), which appears to suppress tumor development. Additionally, this review discusses the efficacy of various treatments, such as molecular therapies that target specific pathways or inhibit neomorphic protein–protein interaction caused by NF2 deficiency. This overview not only expands on the fundamental understanding of NF2 pathophysiology but also explores the potential of novel therapeutic targets that affect the clinical approach to NF2 syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurofibromatosesNeurofibromin 2NeurilemmomaSkin NeoplasmsHumansAnimalsNeurofibromatosis 2MutationSignal TransductionMolecular Targeted Therapy

Stichwörter der Autor:innen

MerlinNF2NF2-related schwannomatosisPPIRKIPRaf kinase inhibitory proteinYAPYes-associated protein 1protein–protein interaction

Substanzen

Neurofibromin 2NF2 protein, human

Autor:innen und Institutionen

  • Rare Disease R&D Center, PRG S&T Co., Ltd., Busan 46274, Republic of Korea.
  • Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 46241, Republic of Korea.

ORCID-Profile: Bae-Hoon Kim, Yeon-Ho Chung, So-Mi Kang

Förderung

  • Pusan National University

Zitieren

APA

Kim, B. H., Chung, Y. H., Woo, T. G., Kang, S. M., Park, S., Kim, M., & Park, B. J. (2024). NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues. International Journal of Molecular Sciences, 25(12), 6558. https://doi.org/10.3390/ijms25126558

Vancouver

Kim BH, Chung YH, Woo TG, Kang SM, Park S, Kim M, et al. NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues. International Journal of Molecular Sciences. 2024;25(12):6558. doi:10.3390/ijms25126558

BibTeX
@article{Kim2024,
  author = {Kim, Bae-Hoon and Chung, Yeon-Ho and Woo, Tae-Gyun and Kang, So-Mi and Park, Soyoung and Kim, Minju and Park, Bum-Joon},
  title = {NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {12},
  pages = {6558},
  doi = {10.3390/ijms25126558}
}
Kostenlos starten →